Ian Haydon, 29, said volunteering was the right thing to do when he shared his story with TODAY last month after receiving the first dose of the vaccine candidate.
Haydon felt some arm pain at the injection site, just like after the first dose, but it came on much more quickly than before, he said.
His partner called the 24-hour hotline for the vaccine study and Haydon was advised to go to urgent care.
Haydon recently found out he received the highest dose of the vaccine tested in the trial — 10 times the amount some other participants were injected with.
In a news release last week, Moderna, Inc., the Massachusetts-based biotechnology company that helped develop the vaccine, said the “most notable adverse events†were seen at this highest dose level — affecting three participants, but only after the second dose.
The company said its vaccine candidate can prompt an immune response in the human body and was found to be safe and well-tolerated in a group of 45 patients.
Haydon said he consented to be in the study and everyone admitted could have received any dose of the vaccine.
Haydon is still in the study and will be monitored periodically for about another year, just like all the other participants, he said
USA
UK
France
Germany
Russia
India
Canada